Evoke Pharma (EVOK) shares have soared after the company announced the results from its pre-NDA meeting with the FDA regarding lead product candidate Gimoti (EVK-001)(metoclopramide nasal spray) for the relief of symptoms related to acute/recurrent diabetic gastroparesis in adult women. The intent of the meeting was to clarify the content of the regulatory, CMC (chemistry, manufacturing and control) and non-clinical sections of the planned filing. Evoke submitted an information package describing the proposed content and format of the sections beforehand. Based on the agency's response to the information package and what was discussed during the meeting, the company believes it has the information it needs to complete the sections in a manner acceptable to the FDA.